Abstracts tagged "Anti-TNF Drugs"

Abstract Number: 1107 • ACR Convergence 2021
Clinical and Genetic Features of Chinese Adult Patients with Chronic Non-bacterial Osteomyelitis: A Single Center Report
Mengzhu Zhao, Min Shen, Di Wu and Keyi Yu, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China (People's Republic)
Background/Purpose: Chronic non-bacterial osteomyelitis (CNO) is a rare polygenic autoinflammatory bone disease. CNO has been seldom reported in the Chinese population. We aimed to characterize…
Abstract Number: 1684 • ACR Convergence 2021
Incidence of Infections in Patients Aged ≥ 50 Years with RA and ≥ 1 Additional Cardiovascular Risk Factor: Results from a Phase 3b/4 Randomized Safety Study of Tofacitinib vs TNF Inhibitors
Andra R Bălănescu¹, Gustavo Citera², Virginia Pascual-Ramos³, Carol A Connell⁴, David Gold⁵, All-shine Chen⁴, Harry Shi⁶, Andrea B Shapiro⁷, Janet Pope⁸ and Hendrik Schulze-Koops⁹, ¹“Carol Davila” University of Medicine and Pharmacy, Department of Internal Medicine and Rheumatology “Sf. Maria” Hospital, Bucharest, Romania, ²Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina, ³Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, ⁴Pfizer Inc, Groton, CT, ⁵Pfizer Inc, Montréal, QC, Canada, ⁶Pfizer Inc, Collegeville, PA, ⁷Pfizer Inc, Peapack, NJ, ⁸University of Western Ontario, London, ON, Canada, ⁹Division of Rheumatology and Clinical Immunology, Department of Internal Medicine IV, University of Munich, Munich, Germany
Background/Purpose: Previous clinical trial and real-world data suggest that risk of serious infection events (SIEs) and opportunistic infections (OIs) is similar with tofacitinib 5 mg…
Abstract Number: 0057 • ACR Convergence 2021
Molecular Profiling of Radiographic Axial Spondyloarthritis Patients Reveals an Association Between Innate and Adaptive Cell Populations and Therapeutic Response to Adalimumab
Rita Torres¹, Daniel Sobral², Ana Fernandes³, Atlas Sardoo⁴, Miguel Bernardes⁵, Patrícia Pinto⁶, Helena Santos⁷, João Gomes⁸, Jose Tavares-Costa⁹, José Silva¹⁰, João Dias¹¹, Alexandra Bernardo⁵, Jean Gailard¹², Jean Armengaud¹³, Vladimir Benes¹⁴, Lúcia Domingues¹⁵, Sara Maia¹⁶, Jaime Branco¹⁷, Ana Varela¹⁸ and Fernando Santos¹⁹, ¹Rheumatology Department, Hospital de Egas Moniz, Centro Hospitalar Lisboa Ocidental, Lisbon, Portugal, ²Faculdade Ciências e Tecnologia, Lisboa, Lisboa, Portugal, ³Instituto de Tecnologia Química e Biológica, Lisboa, Portugal, ⁴CEDOC, NOVA Medical School, UNL, Lisboa, Lisboa, Portugal, ⁵Rheumatology Department, Centro Hospitalar Universitário de São João EPE, Porto, Portugal, ⁶Centro Hospitalar de Vila Nova de Gaia/Espinho, Vila Nova de Gaia, Portugal, ⁷Portuguese Institute of Rheumatology, Lisbon, Portugal, ⁸Hospital Egas Moniz, Lisboa, Lisboa, Portugal, ⁹Rheumatology Department - Unidade Local de Saude do Alto Minho, Ponte de Lima, Portugal, ¹⁰Centro Hospitalar e Universitário de Coimbra, Coimbra, Portugal, ¹¹Centro Hospitalar Médio Tejo, Abrantes, Portugal, ¹²Centre dénergie atomique; Service de Pharmacologie et Immunoanalyse (SPI), Paris, France, ¹³Service de Pharmacologie et Immunoanalyse (SPI), Paris, France, ¹⁴The European Molecular Biology Laboratory, Heidelberg, Germany, ¹⁵CEDOC - Chronic Diseases Research Center - Nova Medical School|Faculdade de Ciências Médicas, Lisboa, Lisboa, Portugal, ¹⁶NOVA Medical School, Nova University of Lisbon, Lisboa, Lisboa, Portugal, ¹⁷EpiDoC Unit, CEDOC, Nova Medical School, Comprehensive Health Research Centre (CHRC), Lisbon, Portugal, ¹⁸Instituto Tecnologia Química e Biológica; Universidade NOVA de Lisboa, Lisboa, Lisboa, Portugal, ¹⁹Hospital Egas Moniz, Lisboa, Portugal
Background/Purpose: The response to treatment in spondylarthropaties is heterogeneous, due to factors yet to be better described. For that reason, it is important to find…
Abstract Number: 0831 • ACR Convergence 2021
Safety and Efficacy of Tofacitinib vs TNF Inhibitors in RA Patients Aged 50 Years or Older with One or More Cardiovascular Risks: Results from a Phase 3b/4 Randomized Safety Trial
Steven R Ytterberg¹, Deepak L Bhatt², Ted Mikuls³, Gary G Koch⁴, Jose L Rivas⁵, Rebecca Germino⁶, Sujatha Menon⁶, Yanhui Sun⁷, Cunshan Wang⁶, Andrea B Shapiro⁸, Keith S Kanik⁶, Carol A Connell⁶ and Roy Fleischmann⁹, ¹Division of Rheumatology, Mayo Clinic, Rochester, MN, ²Department of Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, ³University of Nebraska Medical Center, Omaha, NE, ⁴Department of Biostatistics, University of North Carolina at Chapel Hill, Chapel Hill, NC, ⁵Pfizer SLU, Madrid, Spain, ⁶Pfizer Inc, Groton, CT, ⁷Pfizer CRDC, Shanghai, China (People's Republic), ⁸Pfizer Inc, Peapack, NJ, ⁹Metroplex Clinical Research Center and University of Texas Southwestern Medical Center, Dallas, TX
Background/Purpose: ORAL Surveillance (NCT02092467) was mandated by the US Food and Drug Administration to assess the relative risk of tofacitinib vs TNF inhibitors (TNFi), based…
Abstract Number: 1222 • ACR Convergence 2021
Drug Response Is Associated with Changes in Specific MicroRNAs in Patients with Rheumatoid Arthritis
Qiong Wu¹, Sheau-Chiann Chen¹, Fei Ye¹, Joseph Solus¹, S. Louis Bridges, Jr.², Jeffrey Curtis³, C. Michael Stein¹ and Michelle Ormseth¹, ¹Vanderbilt University Medical Center, Nashville, TN, ²Hospital for Special Surgery, New York, NY, ³Division of Clinical Immunology and Rheumatology, Department of Medicine, Department of Epidemiology, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: MicroRNAs are markers and mediators of disease and drug response. Prior studies have proposed several miRNAs for prediction of drug response or monitoring drug…
Abstract Number: 1806 • ACR Convergence 2021
Designing a Phase 3b, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Investigate the Effect of Guselkumab (TREMFYA®/sup>) Dosing Interval in Psoriatic Arthritis Patients with Inadequate Response to Tumor Necrosis Factor Inhibition
Alexis Ogdie-Beatty¹, Joseph Merola², Philip Mease³, Christopher Ritchlin⁴, Jose Scher⁵, Daphne Chan⁶, Soumya Chakravarty⁷, Wayne Langholff⁸, Olivia Choi⁹, Yevgeniy Krol⁹, Katelyn Rowland⁹ and Alice Gottlieb¹⁰, ¹University of Pennsylvania, Philadelphia, PA, ²Harvard Medical School, Brigham and Women’s Hospital, Boston, MA, ³Swedish Medical Center/Providence St. Joseph Health and University of Washington, Seattle, WA, ⁴Division of Allergy, Immunology, and Rheumatology, School of Medicine and Dentistry, University of Rochester Medical Center, Rochester, NY, ⁵New York University School of Medicine, New York, NY, ⁶Janssen Scientific Affairs, LLC, Spring House, PA, ⁷Janssen Scientific Affairs, LLC and Drexel University College of Medicine, Horsham, PA, ⁸Janssen Research & Development, LLC, Spring House, PA, ⁹Janssen Scientific Affairs, LLC, Horsham, PA, ¹⁰Icahn School of Medicine at Mount Sinai, New York, NY
Background/Purpose: Tumor necrosis factor inhibitors (TNFi) are frequently chosen as the first biologic therapy for patients (pts) with PsA, though a sizeable proportion of pts…
Abstract Number: 0087 • ACR Convergence 2021
TNF Inhibitors and the Risk of Adverse COVID-19 Outcomes in Patients with Immune-Mediated Inflammatory Disease: Pooled Data from Three Global Registries
Zara Izadi¹, Erica Brenner², Satveer Mahil³, Nick Dand⁴, Zenas Yiu⁵, Mark Yates⁴, Ryan Ungaro⁶, Xian Zhang², Manasi Agrawal⁶, Jean-Frederic Colombel⁷, Milena Gianfrancesco¹, Kimme Hyrich⁵, Anja Strangfeld⁸, Loreto Carmona⁹, Elsa Frazão Mateus¹⁰, Saskia Lawson-Tovey⁵, Eva Klingberg¹¹, Giovanna Cuomo¹², Marta Caprioli¹³, Rene-Marc FLIPO¹⁴, Ana Rita Cruz-Machado¹⁵, Carolina Mazeda¹⁶, Rebecca Hasseli¹⁷, Alexander Pfeil¹⁸, Hanns-Martin Lorenz¹⁹, Laura Trupin²⁰, Stephanie Rush¹, Patricia Katz¹, Gabriela Schmajuk¹, Lindsay Jacobsohn²¹, Andrea Seet¹, Samar Al Emadi²², Leanna Wise²³, Emily Gilbert²⁴, Ali Duarte-Garcia²⁵, Maria Valenzuela-Almada²⁶, Carolina Isnardi²⁷, Rosana Quintana²⁷, Enrique Soriano²⁸, Tiffany Hsu²⁹, Kristin D'Silva³⁰, Jeffrey Sparks³¹, Naomi Patel³⁰, Viviane de Souza³², Licia Maria Henrique Mota³³, Ana Paula Reis³⁴, Zachary S. Wallace³⁵, Suleman Bhana³⁶, Wendy Costello³⁷, Rebecca Grainger³⁸, Jonathan Hausmann³⁹, Jean Liew⁴⁰, Emily Sirotich⁴¹, Paul Sufka⁴², Philip Robinson⁴³, Pedro Machado⁴⁴, Christopher Griffiths⁴⁵, Jonathan Barker⁴, Catherine smith⁴, Jinoos Yazdany¹ and Michael Kappelman², ¹University of California San Francisco, San Francisco, CA, ²University of North Carolina at Chapel Hill, Chapel Hill, NC, ³St John’s Institute of Dermatology, London, United Kingdom, ⁴King's College London, London, United Kingdom, ⁵University of Manchester, Manchester, United Kingdom, ⁶Icahn School of Medicine at Mount Sinai, New York, NY, ⁷MD, New York, NY, ⁸Deutsches Rheuma-Forschungszentrum Berlin, Berlin, Germany, ⁹Instituto de Salud Musculoesqueltica (InMusc), Madrid, Spain, ¹⁰Liga Portuguesa Contra as Doenças Reumáticas (LPCDR), Lisbon, Portugal, ¹¹University of Gothenburg, Gothenburg, Sweden and Sahlgrenska University Hospital, Gothenburg, Sweden, ¹²Università degli Studi della Campania Luigi Vanvitelli, Napoli, Italy, ¹³IRCCS Humanitas Research Hospital, Milan, Italy, ¹⁴Rheumatology Department, Lille University Hospital, Lille, France, ¹⁵Rheumatology Department, Hospital de Santa Maria, Centro Hospitalar Universitário Lisboa Norte, Lisbon Academic Medical Center; Rheumatology Research Unit, Instituto de Medicina Molecular João Lobo Antunes, Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal, ¹⁶Rheumatology Department - Centro Hospitalar do Baixo Vouga and Ibimed, Institute for Biomedicine, University of Aveiro, Aveiro, Portugal, ¹⁷Justus-Liebig-University Giessen, Bad Nauheim, Germany, ¹⁸Friedrich Schiller University Jena, Jena, Germany, ¹⁹University Hospital Heidelberg Germany, Heidelberg, Germany, ²⁰UC San Francisco, San Francisco, CA, ²¹University of California San Francisco, Antioch, CA, ²²Hamad medical corporation, Doha, Qatar, ²³LAC+USC/Keck Medicine of USC, Pasadena, CA, ²⁴Mayo Clinic, Jacksonville, FL, ²⁵Mayo Clinic, Rochester, MN, ²⁶Division of Rheumatology, Mayo Clinic, Rochester, MN, ²⁷Argentine Society of Rheumatology, Buenos Aires, Argentina, ²⁸Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, ²⁹Brigham and Women's Hospital, Jamaica Plain, MA, ³⁰Massachusetts General Hospital, Boston, MA, ³¹Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, ³²UFJF, JUIZ DE FORA, Brazil, ³³Universidade de Brasília, Brasilia, Brazil, ³⁴Centro Universitrio de Braslia- UniCEUB, Brasilia, Brazil, ³⁵Harvard Medical School, Boston, MA, ³⁶Crystal Run Health, Montvale, NJ, ³⁷Irish Children's Arthritis Network, Bansha, Ireland, ³⁸University of Otago, Wellington, New Zealand, ³⁹Boston Children's Hospital / Beth Israel Deaconess Medical Center, Cambridge, MA, ⁴⁰Boston University, Boston, MA, ⁴¹McMaster University, Hamilton, ON, Canada, ⁴²HealthPartners, Eagan, MN, ⁴³University of Queensland School of Clinical Medicine, Brisbane, Australia, ⁴⁴Centre for Rheumatology & Department of Neuromuscular Diseases, University College London, London, United Kingdom, ⁴⁵University of Manchester, Manchester Centre for Dermatology Research, Manchester, United Kingdom
Background/Purpose: While tumor necrosis factor inhibitors (TNFi) are widely prescribed globally due to their high efficacy across immune-mediated inflammatory diseases (IMIDs), the impact of COVID-19…
Abstract Number: 0834 • ACR Convergence 2021
Comparative Effectiveness of TNF Inhibitor vs IL-6 Receptor Inhibitor as Monotherapy or Combination Therapy with Methotrexate in Patients with Rheumatoid Arthritis: Analysis from CorEvitas’ RA Registry
Anthony Sebba¹, Clifton Bingham², Vivian Bykerk³, Stefano Fiore⁴, Kerri Ford⁵, Jud C Janak⁶, Dimitrios Pappas⁶, Taylor Blachley⁶, Swapna Dave⁶, Joel Kremer⁷, Miao Yu⁶ and Ernest Choy⁸, ¹Division of Rheumatology, University of South Florida, Tampa, FL, ²Johns Hopkins University, Baltimore, MD, ³Division of Rheumatology, Hospital for Special Surgery, New York City, NY, ⁴Sanofi, Bridgewater, NJ, ⁵Sanofi, Cambridge, MA, ⁶CorEvitas, LLC, Waltham, MA, ⁷Department of Medicine, Center for Rheumatology, Albany Medical College, Albany, FL, ⁸CREATE Centre, Cardiff University, Cardiff, Wales, United Kingdom
Background/Purpose: RA patients who fail to achieve treatment targets with conventional synthetic DMARDs (csDMARDs) can be treated with biologics. Randomized controlled trials (RCTs) have shown…
Abstract Number: 1233 • ACR Convergence 2021
Physician and Patient Reported Effectiveness Outcomes Are Similar in Tofacitinib and TNF Inhibitors in Rheumatoid Arthritis Patients: Data from a Rheumatoid Arthritis Registry in Canada
Mohammad Movahedi¹, Angela Cesta², Xiuying Li², Edward Keystone³ and Claire Bombardier⁴, ¹Toronto General Hospital Research Institute, University Health Network, Toronto, ON, Canada, ²Toronto General Hospital Research Institute, UHN, Toronto, ON, Canada, ³Keystone Consulting Enterprises Inc., Toronto, ON, Canada, ⁴University of Toronto - Toronto, Toronto, ON, Canada
Background/Purpose: Tofacitinib (TOFA) is an oral, small molecule drug used for rheumatoid arthritis (RA) treatment as an alternative option to biologic disease modifying antirheumatic drugs…
Abstract Number: 1830 • ACR Convergence 2021
Discontinuation of Tumor Necrosis Factor Inhibitors in Psoriatic Arthritis and Psoriasis
Sophia Wolfe¹, Elizabeth Cheng², Kavya Ganuthula¹, Meika Fang³, Gail Kerr⁴, Jessica Walsh⁵, Elizabeth Chang⁶, Siba Raychaudhuri⁷, Kyle Brees², Robert Dellavalle¹, Andreas Reimold⁸ and Liron Caplan⁹, ¹Rocky Mountain Regional VAMC/University of Colorado School of Medicine, Aurora, CO, ²Rocky Mountain Regional VAMC, Aurora, CO, ³David Geffen School of Medicine at UCLA/West Los Angeles Veterans Affairs Medical Center (VAMC), Los Angeles, CA, ⁴Washington D.C., Veterans Affairs Medical Center (VAMC)/Georgetown and Howard Universities, Washington, DC, ⁵Salt Lake City Veteran Affairs Medical Center (VAMC)/University of Utah Hospital, Salt Lake City, UT, ⁶Phoenix VAMC, Phoenix, AZ, ⁷Sacramento Veterans Affairs Medical Center (VAMC)/University of California-Davis Health, Davis, CA, ⁸University of Texas – Southwestern Medical Center/Dallas Veterans Affairs Medical Center (VAMC), Dallas, TX, ⁹Rocky Mountain Regional Veterans Affairs Medical Center (VAMC)/University of Colorado School of Medicine, Aurora, CO
Background/Purpose: Psoriatic arthritis (PsA) is a chronic inflammatory disease of the joints and skin that affects 1/1000 people in the US. Tumor necrosis factor-alpha (TNF-α)…
Abstract Number: 0601 • ACR Convergence 2020
The “Why” of Drug Discontinuation; Clinical Review of EMR Notes for 2,545 Patients with Rheumatic Diseases
Kent Kwas Huston¹, Simon Helfgott², Scott Milligan³, Jasvinder Singh⁴, Nehad Soloman⁵, Brandon Weil³ and Colin Edgerton⁶, ¹Kansas City Physician Partners, Kansas City, MO, ²BWH- HMS, Boston, MA, ³Trio Health, Louisville, CO, ⁴University of Alabama at Birmingham, Birmingham, AL, ⁵Arizona Arthritis & Rheumatology Associates, P.C., Peoria, AZ, ⁶Articularis Healthcare, Summerville, SC
Background/Purpose: Persistence on therapy is an important consideration in rheumatic diseases. There are multiple treatment options that influence long term disease management and a better…
Abstract Number: 0883 • ACR Convergence 2020
Network Meta-Analysis of Long-Term Efficacy (ASAS40) of Biologic Disease-Modifying Anti-Rheumatic Drugs (bDMARDs) in bDMARD-Naïve Patients with Non-Radiographic Axial Spondyloarthritis
Sandeep Kiri¹, Mindy Kim², Marissa Betts³, Madhura Chitnis³, Kyle Fahrbach³, Jialu Tarpey³ and Monica Turner³, ¹UCB Pharma, Slough, England, United Kingdom, ²UCB Pharma, Smyrna, GA, ³Evidera, Waltham
Background/Purpose: Biologic disease-modifying anti-rheumatic drugs (bDMARDs) have demonstrated large clinical improvements in patients with non-radiographic axial spondyloarthritis (nr-axSpA), with patients naïve to bDMARDs experiencing substantial…
Abstract Number: 1362 • ACR Convergence 2020
BASDAI Guided Treat-to-target Tapering of Tumor Necrosis Factor Inhibitors in Axial Spondyloarthritis: Results of the Retrospective TAPAS Study
Nathan den Broeder¹, Michelle Mulder¹, Mark Wenink¹, Alfons den Broeder¹, Lise Verhoef², Frank van den Hoogen¹ and C.A.J Michielsens¹, ¹Sint Maartenskliniek, Nijmegen, Netherlands, ²Sint Maartenskliniek, Nijmegen, Gelderland, Netherlands
Background/Purpose: Tumor Necrosis Factor inhibitors (TNFi) have proven to be safe and effective in the treatment of axial spondyloarthritis (axSpA). However, they carry some disadvantages,…
Abstract Number: 0642 • ACR Convergence 2020
COVID-19 Infection in Rheumatologic Patients on Treatment with Targeted Therapies
Marta González Fernández¹, Orlando Pompei fernández², Joaquín María Belzunegui Otano³, Paula García Escudero¹, Claudia Stoye², Juan Ramón De Dios², Belén Álvarez Rodríguez², Elena Garmendia Sánchez¹, Susana Gil², Ana Ruibal-Escribano⁴, Margarida Vasques Rocha², Francisco García Llorente⁵, César Antonio Egües⁶, Edurne Guerrero⁷ and Jaime Calvo-Alén², ¹Hospital Universitario Cruces, Barakaldo, Spain, ²Hospital Universitario Araba, Vitoria-Gasteiz, Pais Vasco, Spain, ³Rheumatology Service, Hospital Universitario Donostia. San Sebastián, Spain, San Sebastian, Spain, ⁴Hospital Alfredo Espinosa, Urduliz, Pais Vasco, Spain, ⁵Hospital Universitario de Galdakao, Galdakao, Pais Vasco, Spain, ⁶Hospital Universitario Donostia, Donostia-San Sebastián, Pais Vasco, Spain, ⁷Hospital Alto Deba, Arrasate, Pais Vasco, Spain
Background/Purpose: SARS COV 2 pandemic has been an issue which has challenged the health care systems around the world. Rheumatology has been involved in two…
Abstract Number: 0897 • ACR Convergence 2020
Temporal Achievement of Clinical Response and Inactive Disease Status in Patients with Axial Spondyloarthritis Treated with Etanercept
Xenofon Baraliakos¹, Annette Szumski², Kenneth Kwok³ and Bonnie Vlahos⁴, ¹Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Bochum, Germany, ²Syneos Health, Princeton, ³Pfizer, New York, NY, ⁴Pfizer, Collegeville, PA
Background/Purpose: Treatment with etanercept (ETN) is effective and well tolerated in patients with axial spondyloarthritis (AS), but the time frames within which patients tend to…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].